Key Highlights

  • Alnylam reported rapid product-revenue growth in 2026 and swung toward profitability.
  • Its treatment for ATTR amyloidosis surpassed $1 billion in sales, driving commercial momentum.
  • The company's RNA interference technology switches off specific disease-causing genes.
  • Expansion into larger patient populations for its approved medicines is a key growth driver.

Alnylam Pharmaceuticals (NASDAQ:ALNY) pioneered an entirely new class of medicine, drugs that silence disease-causing genes, and it is now turning that science into fast-growing commercial products. As those medicines reach more patients, Alnylam brings the promise of RNA-based therapies into the Nasdaq 100 growth debate, offering a distinctive biotechnology story.

What Alnylam Does

Alnylam is a biopharmaceutical company built around a technology called RNA interference, or RNAi, which switches off specific genes that cause disease. It sits in the healthcare sector. After years of scientific development, it has brought several RNAi medicines to market, treating rare and increasingly less-rare conditions. Its approach can offer durable effects with infrequent dosing, sometimes just a couple of injections a year, which is attractive for chronic conditions, and it has built the expertise to design and deliver these novel therapies.

Commercial Momentum Builds

Alnylam has reached an important inflection point, turning its science into strong commercial growth. In 2026 it reported rapid product-revenue growth and swung towards profitability, with its treatment for a form of a serious heart and nerve condition, ATTR amyloidosis, surpassing a billion dollars in sales and driving momentum. This matters because Alnylam has moved from being a research-stage company burning cash to one generating substantial, growing Revenue from approved products. Its expansion into larger patient populations, particularly for the ATTR condition, has broadened its market considerably. Turning pioneering science into commercially successful, profitable products is the crucial transition, and Alnylam has been demonstrating it can do so.

Why it Matters for the Nasdaq 100

Alnylam offers the index exposure to an innovative and growing class of medicine, and to a biotechnology company transitioning from research to commercial success. Its results reveal how well a novel therapeutic approach is translating into revenue. As a member of the benchmark, it provides Diversification into healthcare innovation, and its progress is watched as a sign of whether pioneering biotechnology platforms can build durable, profitable franchises.

From Platform to Products

Alnylam's transition deserves particular attention, because it illustrates a pivotal moment for any biotechnology company built on a new technology. For years, Alnylam invested heavily in developing its RNAi platform, spending large sums on research with little revenue, a common and risky phase. The pay-off comes when that science produces approved medicines that patients need and insurers will fund, generating revenue that can eventually exceed the costs. Alnylam has reached that stage, with growing product sales and improving profitability, validating both its technology and its Business model. The opportunity now is to expand its approved medicines into larger patient groups and to advance its pipeline of further RNAi therapies, potentially building a broad franchise. The risk is that commercial success attracts competition, that expansion into larger markets brings new challenges, and that not every pipeline candidate will succeed, so continued execution is essential.

The Risks to Weigh

Drug development remains uncertain, and pipeline setbacks can happen. Competition, including from other companies developing treatments for the same conditions, is a growing threat, particularly in the ATTR market. Alnylam's valuation reflects high growth expectations. Pricing and reimbursement pressures affect its medicines. Its reliance on a few key products concentrates risk, and the shares can move sharply on clinical or commercial news.

From Research Platform to Profitable Franchise

Readers should track product-revenue growth, especially for its ATTR treatment, and watch its progress towards sustained profitability. The expansion of its medicines into larger patient populations is a key growth driver. Clinical progress across its RNAi pipeline indicates future products. Commentary on competition, particularly in the ATTR market, reveals pressures. Margins and cash generation show the strength of the business. Finally, watch how well Alnylam converts its pioneering science into a broad, durable franchise, because its value rests on turning RNA-based medicines into a growing portfolio of treatments.